Actively Recruiting
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Led by Pfizer · Updated on 2026-05-05
780
Participants Needed
1
Research Sites
657 weeks
Total Duration
On this page
Sponsors
P
Pfizer
Lead Sponsor
P
PPD, Part of Thermo Fisher Scientific
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
CONDITIONS
Official Title
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women diagnosed with migraine who have taken at least one dose of rimegepant during pregnancy or up to 3 days before conception
- Pregnant women diagnosed with migraine who have not taken rimegepant before or during pregnancy
You will not qualify if you...
- Women who have taken other calcitonin gene-related peptide antagonists, CGRP monoclonal antibodies, or ditans during pregnancy or just before pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Evidera, a PPD business unit
Wilmington, North Carolina, United States, 28401
Actively Recruiting
Research Team
P
Pfizer Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here